BioXcel shareholders elect three Class II directors, ratify Ernst & Young as auditor

BioXcel Therapeutics, Inc.

Elected directors: Sandeep Laumas (12,360,360 for, 8,899,824 withheld), Michael Miller (21,149,269 for, 110,915 withheld), Michal Votruba (18,041,794 for, 3,218,390 withheld).
Ratified Ernst & Young as auditor for FY2023 with 24,849,840 for, 51,173 against, 7,597 abstained.
Turnout was 24,908,610 shares (85.42% of outstanding) as of April 27, 2023 record date.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BioXcel Therapeutics, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. at the 2023-06-26 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-26

Exact text from the filing

Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 24,849,840 51,173 7,597 0

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BioXcel Therapeutics, Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders in 2026 and until his successor has been duly elected and qualified. at the 2023-06-26 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-26

Exact text from the filing

NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Sandeep Laumas, M.D. 12,360,360 8,899,824 3,648,426 Michael Miller 21,149,269 110,915 3,648,426 Michal Votruba, M.D. 18,041,794 3,218,390 3,648,426

View on SEC.gov

Browse all shareholder votes →

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-077126

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.